LRB-2616/1
MED:eev:eev
2013 - 2014 LEGISLATURE
February 11, 2014 - Introduced by Representatives Hebl, Sargent, Hulsey, Bies,
Wachs, Berceau, Pope and Ohnstad, cosponsored by Senator Miller.
Referred to Committee on Health.
AB751,1,4
1An Act to renumber and amend 254.52 (1);
to amend 254.52 (title); and
to
2create 254.52 (1) (b) and 254.52 (3) of the statutes;
relating to: required
3notices by a health care provider who orders a test for the presence of Lyme
4disease.
Analysis by the Legislative Reference Bureau
Under current law, the Department of Health Services (DHS) must conduct
various activities related to researching, monitoring, and providing education about
the spread and incidence of Lyme disease in humans, including developing and
distributing information about Lyme disease through the offices of physicians and
local health departments. This bill requires the Department of Health Services
(DHS) to create and make available on the Internet a form with a notice for patients
who receive certain specified laboratory tests for the presence of Lyme disease. The
form must contain a notice informing the patient: 1) about the prevalence of Lyme
disease in the United States; 2) about the potential for a false negative or false
positive test result for the presence of Lyme disease; and 3) that a patient whose test
is negative should contact his or her health care provider about being retested for
Lyme disease if the patient continues to experience symptoms. The bill requires a
health care provider who orders a specified test for the presence of Lyme disease for
a patient to provide the patient with a copy of the form and requires DHS to update
the form annually to account for the most recent statistics and for additional tests
that are developed to detect the presence of Lyme disease and that warrant the
notice.
For further information see the state fiscal estimate, which will be printed as
an appendix to this bill.
The people of the state of Wisconsin, represented in senate and assembly, do
enact as follows:
AB751,1
1Section
1. 254.52 (title) of the statutes is amended to read:
AB751,2,2
2254.52 (title)
Lyme disease; treatment, information and research.
AB751,2
3Section
2. 254.52 (1) of the statutes is renumbered 254.52 (1) (intro.) and
4amended to read:
AB751,2,55
254.52
(1) (intro.) The department shall
perform do all of the following:
AB751,2,6
6(a) Perform research relating to Lyme disease in humans.
AB751,3
7Section
3. 254.52 (1) (b) of the statutes is created to read:
AB751,2,98
254.52
(1) (b) 1. Create and make available on the Internet a form with the
9following notice to be provided to patients under sub. (3):
AB751,2,12
10"According to the Centers for Disease Control and Prevention (CDC), as of
11[YEAR], Lyme disease is the [RANKING] most common disease in the United States,
12of the diseases that must be reported to the CDC.
AB751,2,2113
Your health care provider has ordered a laboratory test for the presence of Lyme
14disease for you. Current laboratory testing for Lyme disease can be problematic and
15standard laboratory tests often result in false negative and false positive results, and
16if done too early, you may not have produced enough antibodies to be considered
17positive because your immune response requires time to develop antibodies. If you
18are tested for Lyme disease, and the results are negative, this does not necessarily
19mean you do not have Lyme disease. If you continue to experience symptoms, you
20should contact your health care provider and inquire about the appropriateness of
21retesting or additional treatment."
AB751,3,2
12. Annually update the first paragraph of the notice under subd. 1. to reflect
2current statistics.
AB751,3,43
3. Include in the form under subd. 1. an explanation of the requirement under
4sub. (3).
AB751,3,85
4. Identify whether any tests for the presence of Lyme disease, in addition to
6the enzyme-linked immunoabsorbent assay, the immunoflorescent assay, and the
7western blot test, that are available to patients warrant the notice under subd. 1. and
8update the form accordingly.
AB751,3,119
5. Translate the form under subd. 1. into Spanish and other languages spoken
10by a significant number of state residents, as determined by the department, and
11update and make available each translated form as provided in this paragraph.
AB751,4
12Section
4. 254.52 (3) of the statutes is created to read:
AB751,3,1713
254.52
(3) (a) In this subsection, "laboratory test for the presence of Lyme
14disease" means the enzyme-linked immunoabsorbent assay, the immunoflorescent
15assay, the western blot test, or any additional test identified by the department under
16sub. (1) (b) 4. as warranting the notice under sub. (1) (b) 1., if the test is being ordered
17to detect the presence of Lyme disease.
AB751,3,2018
(b) A health care provider who orders a laboratory test for the presence of Lyme
19disease for a patient shall provide to the patient or the patient's legal representative
20an up-to-date copy of the form created by the department under sub. (1) (b).
